BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 26213140)

  • 1. Prostate-specific membrane antigen as a target for cancer imaging and therapy.
    Kiess AP; Banerjee SR; Mease RC; Rowe SP; Rao A; Foss CA; Chen Y; Yang X; Cho SY; Nimmagadda S; Pomper MG
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):241-68. PubMed ID: 26213140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
    Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
    Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
    Plichta KA; Graves SA; Buatti JM
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA).
    Moon SH; Yang BY; Kim YJ; Hong MK; Lee YS; Lee DS; Chung JK; Jeong JM
    Nanomedicine; 2016 May; 12(4):871-879. PubMed ID: 26739097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
    Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
    Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
    Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation and Pilot Clinical Study of Al
    Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
    J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
    Barrio M; Fendler WP; Czernin J; Herrmann K
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of radiolabeled PSMA ligands for tumor imaging.
    Shahrokhi P; Masteri Farahani A; Tamaddondar M; Rezazadeh F
    Chem Biol Drug Des; 2022 Jan; 99(1):136-161. PubMed ID: 34472217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.
    Miyahira AK; Soule HR
    J Nucl Med; 2022 Mar; 63(3):331-338. PubMed ID: 34675109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
    Arsenault F; Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
    Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
    Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG
    Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
    Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of Prostate-Specific Membrane Antigen Using [
    Rowe SP; Gorin MA; Pomper MG
    PET Clin; 2017 Jul; 12(3):289-296. PubMed ID: 28576167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
    Emmett L
    Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.